Newly Hong Kong-listed biotech firm Insilico Medicine is expected to receive up to US$888 million from a French drug maker ...

In the realm of modern medicine, RNA-based therapies have emerged as a promising avenue, with significant advancements in metabolic diseases, oncology, and preventive vaccines. A recent article ...

Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial ...

To sum up, GH001 has shown us pretty robust efficacy, a strong safety profile, and durable antidepressant effects. Going into ...

Explore the challenges faced by Indian pharma in developing rare disease drugs and potential solutions for innovation and cost reduction.

A drug once designed for dengue virus, then quietly abandoned by industry, is suddenly back in the spotlight, and it may be ...

After raising $293 million in the IPO, Insilico Medicine aims to become “a massive source of innovative drugs for pharma ...

CYB003/CYB004 clinical catalysts into 2026, $248M cash runway, equity raises risk, valuation optionality. Click for this CYBN ...

The House will return from a holiday break to face sagas that have vexed the chamber for months. Debates on health care and ...

The approval marks the first new pharmacologic treatment in motion sickness in over four decades. The US Food and Drug ...

The National Human Rights Committee (NHRC) announced the convention of its fourth national forum titled "Human Rights at the Core of Combating Drugs: Challenges and Prospects for Sustainable Solutions ...

Researchers identify a shared RNA-protein interaction that could lead to broad-spectrum antiviral treatments for ...